Fortis Healthcare Ltd
FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. [1]
Strengths
- +Company has been maintaining a healthy dividend payout of 78.2%
Weaknesses
- −Stock is trading at 7.86 times its book value
- −Company has low interest coverage ratio.
- −Company has a low return on equity of 1.13% over last 3 years.
- −Earnings include an other income of Rs.164 Cr.
Shareholding Pattern
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 31.17% | 31.17% | 31.17% | 31.17% | 31.17% | 31.17% | 31.17% | 31.17% |
| FIIs | 23.31% | 25.26%▲2.0 | 26.77%▲1.5 | 27.4%▲0.6 | 27.18%▼0.2 | 27.9%▲0.7 | 27.84%▼0.1 | 25.98%▼1.9 |
| DIIs | 32.31% | 30.73%▼1.6 | 30.05%▼0.7 | 29.46%▼0.6 | 29.79%▲0.3 | 29.14%▼0.6 | 29.33%▲0.2 | 31.35%▲2.0 |
| Public | 13.22% | 12.83%▼0.4 | 12.02%▼0.8 | 11.98%▼0.0 | 11.87%▼0.1 | 11.79%▼0.1 | 11.65%▼0.1 | 11.5%▼0.2 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 294 | 291 | 307 | 333 | 357 | 367 | 388 | 433 | 456 | 443 |
| Expenses | 255 | 242 | 238 | 275 | 297 | 300 | 318 | 345 | 356 | 344 |
| Operating Profit | 40 | 49 | 69 | 58 | 60 | 67 | 71 | 88 | 100 | 99 |
| OPM % | 13% | 17% | 23% | 17% | 17% | 18% | 18% | 20% | 22% | 22% |
| Net Profit | 95 | 23 | 68 | 27 | 40 | 40 | -42 | 52 | 125 | 28 |
| EPS ₹ | 1.26 | 0.3 | 0.91 | 0.36 | 0.52 | 0.52 | -0.56 | 0.69 | 1.66 | 0.38 |
AI Insights
TTM revenue at ₹1,720Cr, up 18.9% YoY. OPM at 21%.
Borrowings at ₹2,030Cr. Debt-to-equity ratio: 0.24x. Healthy balance sheet.
CWIP at ₹55Cr (4% of fixed assets). Moderate ongoing capital expenditure.
DIIs: 31.35% (+9.18pp change). FIIs: 25.98% (-4.05pp change). Promoters hold 31.17%.
ROCE improving from 3% (Mar 2014) to 3% (Mar 2025). Working capital days: -165.
PE 415x with 3.27% ROCE. Price is 686% above book value of ₹122. Dividend yield: 0.1%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2d
- Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) And Recommendation Of Final Dividend 2d - Board to meet on May 22, 2026 to approve FY26 audited results and consider final dividend.
- Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 ('SEBI Listing Regulations') Regarding A Material Litigation Filed By Northern TK Venture Pte Ltd. ('NTK'), The Promoter Shareholder Of The Company, Against Daiichi Sankyo Company Limited Before The Tokyo District Court In Japan. 29 Apr - Tokyo District Court proceedings on NTK claim concluded; judgment scheduled for 10 September 2026.
- Intimation Of Grant Of Employee Stock Options ('Options') Under 'Fortis Healthcare Limited Employee Stock Option Scheme 2026." 23 Apr - Fortis Healthcare approved grant of up to 1.32 crore ESOPs on April 23, 2026 at ₹923.10 each.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 Apr
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse